#DDDD @4dpharmaplc

A huge clinical pipeline of innovative, patent-protected therapies with results due on 3 of them ( #COVID19 included) before year-end. 5 Phase-2 candidates. An R&D and licensing deal with @Merck $MRK (5.83% owners) worth up to $1bn. Market cap - £100m. (1/7)

There is RNS-stated potential for a US listing, where a similar live bio-therapeutics stock Seres $MCRB did 6x on a successful gastroenterology Phase 3 read-out. They now command a $2bn mcap, versus #DDDD at £100m (c. 18x) based on ONE Phase 3 success. (2/7)

The last ‘small’ biotech I saw with 5 Phase-2 candidates was $AXSM which I bought at $4 (c. $100m mcap). On the first Phase-3 success this went to c. $30, on the second it hit $100 (25x). This happened within 18 months. (3/7)

The selling of the Woodford holding this summer artificially depressed the share price when the market was flooded with shares. This has now been buoyed by Seres’ success, and we are now firmly in an upwards trend. (4/7)

Deducting the £20m of cash, you have an EV of £80m which, despite doubling in a month, still looks drastically cheap versus peers in the space. Management have invested £2.5m this year alone, and own c. 25%. (5/7)

#DDDD has genuine potential to become a world leader in a huge, multi-billion pound, growing market. The drugs use naturally occurring, but targeted bacteria which give improved safety profiles over comparable drugs. $MCRB proved it works. (6/7)

#DDDD have over 1000 patents, proprietary programmes in oncology, respiratory (asthma & #COVID19), CNS, and immune-inflammatory conditions. The deal with Merck is worth up to $1bn alone. They have their own commercial scale manufacturing facilities.

My favourite biotech. (7/7)